Semaglutide 10 mg

Descripción

Semaglutide is a long-acting GLP-1 receptor agonist engineered to mimic the activity of endogenous glucagon-like peptide-1 while providing substantially longer biological activity than the native hormone. Unlike Tirzepatida y Retatrutida, Semaglutide activates only the GLP-1 receptor, making it the simplest member of the current generation of incretin peptides. This selective mechanism has made Semaglutide one of the most extensively investigated metabolic peptides in both preclinical and clinical research over the past decade.

Because of this large body of evidence, Semaglutide is frequently used as the reference compound when evaluating newer dual- and triple-receptor agonists.

Why Semaglutide remains important in metabolic research

Although newer multi-receptor agonists have attracted considerable attention, Semaglutide continues to serve as the scientific benchmark for GLP-1 biology.

Published research has investigated Semaglutide in relation to:

• appetite regulation
• body-weight reduction
• glycaemic control
• insulin secretion
• gastric emptying
• cardiovascular outcomes
• metabolic syndrome
• non-alcoholic fatty liver disease
• long-term incretin signalling

Its extensive clinical literature makes Semaglutide one of the most important comparator molecules in obesity and metabolic research. Many modern studies evaluating Tirzepatide, Retatrutide and emerging GLP-1 combinations use Semaglutide as the reference standard.

How Semaglutide works

Semaglutida selectively activates the GLP-1 receptor, a key regulator of appetite, glucose homeostasis and gastrointestinal signalling.

Activation of GLP-1 receptors has been associated in published research with:

• glucose-dependent insulin secretion
• suppression of glucagon release
• delayed gastric emptying
• reduced food intake
• altered central appetite signalling
• improvements in several metabolic markers

Unlike Tirzepatide, Semaglutide does no activate GIP receptors. Unlike Retatrutide, it has no glucagon receptor activity.

Its value therefore lies in providing a well-characterised single-pathway GLP-1 model, making it the logical comparator for newer incretin compounds.

Published clinical findings on Semaglutide

Semaglutide has one of the largest human evidence bases of any peptide currently used in metabolic research.

In the STEP clinical programme, once-weekly Semaglutide produced substantial reductions in body weight over 68-week treatment periods, establishing GLP-1 receptor agonism as a major therapeutic strategy for obesity research.

Beyond weight-related outcomes, multiple large clinical programmes have demonstrated improvements in:

• HbA1c
• fasting glucose
• waist circumference
• blood pressure
• selected cardiovascular outcomes
• cardiometabolic risk markers

Because these findings have been reproduced across numerous independent trials, Semaglutide remains the principal benchmark against which newer dual- and triple-agonist peptides are evaluated.

Resultados publicados de seguridad y tolerabilidad

Published clinical studies consistently identify gastrointestinal events as the most common adverse effects associated with Semaglutide. Frequently reported events include: nausea, vomiting, diarrhoea, constipation and abdominal discomfort.

Across the major clinical programmes, these events were generally most pronounced during dose escalation and were typically described as leve a moderado in severity. As with other GLP-1 receptor agonists, gradual dose escalation was an important component of the published research protocols used to improve tolerability.

This section summarises published findings on investigational and clinical Semaglutide research and is not intended as guidance for use of this product.

Published dosing schedules used in Semaglutide research

Published Semaglutide studies generally employed once-weekly administration with gradual dose escalation, allowing investigators to evaluate both efficacy and gastrointestinal tolerability over extended treatment periods.

Across the major obesity and diabetes programmes, escalation protocols were used before reaching maintenance doses, with studies continuing for up to 68 weeks in obesity research. The published literature therefore reflects structured clinical trial design rather than a single universal dosing schedule.

These schedules summarise published clinical research design and are not instructions for use of this product.

Semaglutide vs Tirzepatide vs Retatrutide

Semaglutida

• GLP-1 receptor agonist
• single receptor mechanism
• largest clinical evidence base
• reference compound for GLP-1 research

Tirzepatida

• GLP-1 + GIP dual agonist
• broader incretin signalling
• frequently compared directly with Semaglutide

Retatrutida

• GLP-1 + GIP + glucagon triple agonist
• broadest receptor profile
• represents the newest generation of multi-receptor metabolic peptides

For researchers investigating incretin biology, Semaglutide provides the foundation from which dual- and triple-agonist compounds can be evaluated.

Características del producto

Aplicación: investigación de laboratorio y análisis
Uso restringido: no apto para consumo humano; no apto para uso médico, veterinario o cosmético
Producido en instalaciones que cumplen con GMP bajo estrictos protocolos de control de calidad.
Cada lote se somete a pruebas de laboratorio exhaustivas después de la producción (puede encontrar el Certificado de Análisis debajo de las imágenes del producto).
Liofilizado (liofilizado) para máxima estabilidad y vida útil prolongada.
Sellado en viales estériles, listo para la reconstitución.
Purity: ≥99% (HPLC-tested)
Appearance: Lyophilized white/off-white powder
Fórmula molecular: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight: 4113.64
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Almacenamiento: los viales liofilizados sin abrir se almacenan mejor refrigerar a 2–8 °C, que es el método de almacenamiento confirmado por nuestro socio de fabricación y adecuado para hasta 24 meses. Se prefiere la refrigeración porque minimiza los ciclos innecesarios de congelación y descongelación durante la manipulación rutinaria. Si se requiere un almacenamiento a más largo plazo, los viales liofilizados sin abrir también pueden mantenerse congelados. Una vez reconstituidos, almacene siempre a 2–8 °C y no congele.

Reconstitución y manipulación

Semaglutide is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with agua bacteriostática Antes de usar. Los péptidos de la clase GLP-1 a veces tardan en disolverse y requieren una reconstitución muy suave para evitar la formación de espuma o que queden ligeramente turbios.

Para otras guías sobre selección de solventes, planificación de concentraciones y almacenamiento, consulte el completo Guía de Reconstitución de Péptidos y Calculadora de Reconstitución.

Estudios clave publicados

• Wilding JPH et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021.
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
• Aroda VR. A Review of the SUSTAIN Clinical Trial Programme. Diabetes, Obesity and Metabolism. 2019.

Preguntas frecuentes

What is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the activity of the naturally occurring incretin hormone glucagon-like peptide-1. It has become one of the most extensively studied metabolic peptides and serves as the reference compound for modern GLP-1 research. Published studies have investigated Semaglutide in relation to appetite regulation, glucose homeostasis, body-weight outcomes and broader cardiometabolic signalling.

How does Semaglutide work?

Semaglutide selectively activates the GLP-1 receptor, a pathway involved in regulating insulin secretion, glucagon release, gastric emptying and appetite signalling. Unlike newer dual- and triple-receptor agonists, it acts only on GLP-1 receptors, making it an important reference molecule for researchers comparing different incretin-based therapeutic strategies.

How is Semaglutide different from Tirzepatide?

Semaglutide activates only the GLP-1 receptor, whereas Tirzepatide is a dual GLP-1/GIP agonist. Both compounds belong to the incretin class, but Tirzepatide expands the mechanism beyond GLP-1 signalling. As a result, Semaglutide is often used as the benchmark against which dual agonists are evaluated in metabolic research.

How is Semaglutide different from Retatrutide?

Retatrutide is a triple agonist that targets GLP-1, GIP and glucagon receptors, giving it the broadest receptor profile currently under investigation among incretin peptides. Semaglutide, by contrast, focuses exclusively on GLP-1 receptor activation. This makes Semaglutide the foundational reference molecule for GLP-1 biology, while Retatrutide represents the next generation of multi-receptor metabolic research.

Why is Semaglutide still important when newer peptides exist?

Although newer dual- and triple-agonist peptides have generated considerable interest, Semaglutide remains one of the most important compounds in metabolic research because it has the largest and most mature body of published clinical evidence. Many studies evaluating Tirzepatide, Retatrutide and other investigational peptides continue to use Semaglutide as the primary comparator, making it central to understanding how newer incretin therapies differ from established GLP-1 receptor agonism.

What research areas commonly investigate Semaglutide?

Published studies have investigated Semaglutide across a broad range of metabolic research areas, including obesity, body-weight regulation, appetite signalling, glucose metabolism, type 2 diabetes, cardiovascular outcomes, fatty liver disease and long-term incretin biology. Its extensive evidence base makes it one of the most frequently referenced peptides in modern metabolic research.

How is Semaglutide supplied?

This product is supplied as 10 mg of lyophilised Semaglutide in a sterile research vial. Each batch is accompanied by a Certificate of Analysis (COA), and independent third-party analytical verification is available for selected batches. The product is intended exclusively for laboratory and analytical research.

¿Está este producto destinado al uso humano?

No. Semaglutide supplied by LIFE Peptide is provided strictly for research use only. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published clinical studies on this page is included solely to summarise the current scientific literature surrounding the Semaglutide molecule.

Contexto de investigación relacionado

Semaglutide belongs to the GLP-1 receptor agonist class within incretin-based metabolic research. For mechanistic comparison with dual and triple agonists, see our Guía de investigación metabólica de GLP-1.

Explorar todos los compuestos en el Categoría de investigación metabólica.

For pathway comparison:

• Dual agonists:  Tirzepatide (GLP-1/GIP)

• Triple agonists: Retatrutide (GLP-1/GIP/glucagon)

NOTE: This is for educational reference only and does not constitute medical advice.

Disclaimer:
Este producto se vende únicamente para fines de investigación. No está destinado a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. El comprador asume toda la responsabilidad por su manipulación y uso adecuados.